Catechol estrogens (CEs) are genotoxic
metabolites whose detection
is challenging due to their low concentrations and high variability
in the blood. By intact protein and free CE measurement of the spiked
hemolysate, endogenous CEs were revealed to mainly (>99%) exist
as
hemoglobin (Hb) adducts in red blood cells. In order to detect endogenous
CE–Hb adducts, we developed a two-step method that involved
protein precipitation and solid phase extraction to purify Hb from
red blood cells, and the method was coupled with proteomics using
liquid chromatography-tandem mass spectrometry. Using bottom-up proteomics
and standard additions, we identified C93 and C112 of Hb-β as
the main adduction sites of Hb, and this accounted for CE-induced
oxidization of adducted peptides by sample preparation. The non-adducted,
adducted, and oxidized tryptic peptides that covered the same Hb-β
sequences were targeted by parallel reaction monitoring to determine
the adduction level in red blood cells. A quantification limit (S/N
< 8) below the endogenous CE–Hb adduction level with relative
standard errors that ranged from 5 to 22% was achieved and applied
to clinical samples. The human serum albumin (HSA) adduction levels
from the same patient were also determined using a previously developed
method (Anal. Chem.
2019,
91, 15922–15931). A positive correlation (R
2 = 0.673) between the CE–HSA and CE–Hb adduction
level was obtained from all clinical samples, and both levels were
significantly (p < 0.005) higher for patients
with breast cancer compared to healthy controls. However, double indexes
derived from the red blood cell and the serum, respectively, provide
higher precision and confidence in predicting cancer risk than the
single index. This study reported an efficient sample preparation
for proteomics-based Hb adducts and revealed the potential of using
multiple blood proteins for developing more reliable and specific
markers based on protein adductomics.